Paper Search Console

Home Search Page Alphabetical List About Contact

Journal Title

Title of Journal: Breast Cancer Res Treat

Search In Journal Title:

Abbravation: Breast Cancer Research and Treatment

Search In Journal Abbravation:

Publisher

Springer US

Search In Publisher:

DOI

10.1016/0090-4295(73)90044-7

Search In DOI:

ISSN

1573-7217

Search In ISSN:
Search In Title Of Papers:

Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort

Authors: Patricia A. Ganz, Laurel A. Habel, Erin K. Weltzien, Bette J. Caan, Steven W. Cole,

Publish Date: 2011/04/11
Volume: 129, Issue:2, Pages: 549-
PDF Link

Abstract

There is increasing interest in the relationship between host lifestyle factors and the outcomes of cancer treatment. Behavioral factors, comorbid conditions, and non-cancer-related pharmaceutical exposures may affect breast cancer (BC) outcomes. We used observational data from the LACE Study cohort (women with early stage BC from the Kaiser Permanente Northern California Cancer Registry) to examine the association between beta blockers (BBs) and/or angiotensin-converting enzyme inhibitors (ACEi) and BC recurrence, BC-specific mortality, and overall mortality. Among 1,779 women, there were 292 BC recurrences, 174 BC deaths, and 323 total deaths. 23% were exposed to either a BB and/or an ACEi. These drugs were associated with older age, postmenopausal status, tamoxifen therapy, greater pre-diagnosis BMI, hypertension, and diabetes. In Cox proportional hazards models, ACEi exposure was associated with BC recurrence (HR 1.56, 95% CI 1.02, 2.39, P = 0.04), but not cause-specific or overall mortality. Combined ACEi and BB were associated with overall mortality (HR 1.94, 95% CI 1.22, 3.10, P = 0.01). BB exposure was associated with lower hazard of recurrence and cause-specific mortality. However, there was no evidence of a dose response with either medication. For recurrence and cause-specific mortality, BB combined with ACEi was associated with a lower HR for the outcome than when ACEi alone was used. These hypothesis generating findings suggest that BC recurrence and survival were associated with exposure to two commonly used classes of anti-hypertensive medications. These observations need to be confirmed and suggest that greater attention should focus on the potential role of these commonly used medications in BC outcomes.Funding source for the conduct of this research was provided to the following authors: Ganz (the Breast Cancer Research Foundation, the Jonsson Comprehensive Cancer Center Foundation, R01 CA109650), Habel (R01 CA98838 and R01 CA129059), Weltzien (R01 CA129059), Caan (R01 CA129059), and Cole (R01 CA116778).


Keywords:

References


.
Search In Abstract Of Papers:
Other Papers In This Journal:

  1. Variability in hormone and growth factor receptor expression in primary versus recurrent
  2. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage
  3. Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort
  4. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast
  5. Feature extraction via composite scoring and voting in breast cancer
  6. Reactive oxygen species induce phosphorylation of serine 118 and 167 on estrogen receptor alpha
  7. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer
  8. Bcl-2 expression correlates with lymphovascular invasion and long-term prognosis in breast cancer
  9. Diagnosis and management of primary breast sarcoma
  10. Recurrent read-through fusion transcripts in breast cancer
  11. Anastrozole versus tamoxifen as adjuvant therapy for Japanese postmenopausal patients with hormone-responsive breast cancer: efficacy results of long-term follow-up data from the N-SAS BC 03 trial
  12. Accuracy of magnetic resonance in suspicious breast lesions: a systematic quantitative review and meta-analysis
  13. Impact of carpal tunnel syndrome surgery on women with breast cancer-related lymphedema
  14. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
  15. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
  16. Body weight and risk of breast cancer in BRCA1/2 mutation carriers
  17. Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients
  18. Patterns of nodal staging during breast conservation surgery in the medicare patient: will the ACOSOG Z0011 trial change the pattern of care?
  19. Tumor angiogenesis as prognostic and predictive marker for chemotherapy dose-intensification efficacy in high-risk breast cancer patients within the WSG AM-01 trial
  20. CYP1B1 and predisposition to breast cancer in Poland
  21. Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized
  22. Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers
  23. The effect of delays in treatment for breast cancer metastasis on survival
  24. Correlation of HER2
  25. TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling
  26. HER3
  27. Metformin and breast cancer risk: a meta-analysis and critical literature review
  28. XRCC2 Arg188His polymorphism is not directly associated with breast cancer risk: evidence from 37

Search Result:



Help video to use 'Paper Search Console'